Product Description
NUC-7738 is a ProTide transformation of 3'-deoxyadenosine (3'-dA), also known as cordycepin. 3'-dA has demonstrated potent anti-cancer activity in non-clinical studies, but has not been successfully developed as a anti-cancer agent due to its rapid breakdown by adenosine deaminase (ADA). It is a nucleoside analog. (Sourced from: https://www.nucana.com/nuc7738.html)
Mechanisms of Action: RNA Synthetase Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nucana
Company Location: Europe
Company Founding Year: 2008
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Nucana presented P2 Melanoma results on 2025-12-10 for Fosdesdenosine sipalabenamide
- Clinical Outcomes Reported - Nucana announced they will present P1 Melanoma|Lymphoma results in 4Q25 for Fosdesdenosine sipalabenamide
- Clinical Outcomes Expected - Nucana announced they will present P1 Melanoma|Lymphoma results in YE26 for Fosdesdenosine sipalabenamide
Highest Development Phases
Phase 2: Lymphoma|Melanoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03829254 |
NuTide:701 | P2 |
Recruiting |
Lymphoma|Melanoma |
2026-08-01 |
2025-08-19 |